RRR was used to compare PD-1/PD-L1 inhibitor monotherapy with combined chemotherapy based on PD-1/PD-L1 inhibitor, and showed that the risk of pruritus, but not rash, was increased (Table 2). Here, PDCD1 is linked to Pruritus.